June 16, 2023 06:33 AM EDTUpdated June 20, 05:55 PM

FDA approves Roche’s second CD20xCD3 bispecific in certain lymphomas

Kyle LaHucik

Senior Reporter

The FDA granted accelerated approval to Genentech’s CD20xCD3 bispecific for patients with a certain type of non-Hodgkin’s lymphoma on Thursday night …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA approves Roche’s second CD20xCD3 bispecific in certain lymphomas

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis highlights overall M&A track record following MorphoSys impairment

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

FDA ap­proves Roche’s sec­ond CD20xCD3 bis­pe­cif­ic in cer­tain lym­phomas

Senior Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

FDA approves Roche’s second CD20xCD3 bispecific in certain lymphomas